This is in line with previous findings in other cohorts that CSF Aβ42 may capture early stage amyloid pathology before amyloid PET.20,21 Similar to A, tau positivity was much higher among CU participants using p-tau, and a greater difference was seen between CSF p-tau and tau PET. The gene discussed is MAPT; the disease is amyloidosis.